|
rs121913377
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Extended BRAF testing using PCR for 9 mutations and VE1 immunohistochemistry for BRAF V600E detection on 95 lesions including 40 primary melanomas with their matched metastases (n = 42), recurrences (n = 9) and second primaries (n = 4) was performed.Nine patients had multiple metastases.
|
25236573 |
2014 |
|
rs121913377
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
In conclusion, there is no prognostic value of BRAF V600E mutation on overall survival in stage I-III melanoma patients, yet its presence might indicate a decreased risk for development of relapse and/or metastasis in stage III melanoma patients.
|
31058533 |
2019 |
|
rs121913377
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
There was no significant correlation with BRAF (V600E) mutation and age, gender, tumor size, ETE, central lymph node metastasis, the status of pT, pN1a-b, and distant metastasis.
|
26951110 |
2016 |
|
rs121913377
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E mutation and BRAF kinase inhibitors in conjunction with stereotactic radiosurgery for intracranial melanoma metastases.
|
27203149 |
2017 |
|
rs121913377
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF(V600E) was characterized in 113 PTC patients diagnosed with pT1aNo-x (one PTC focus with a diameter <1 cm, without lymph node or distant metastases according to IUCC/AJCC TNM staging system 2010).
|
24354346 |
2014 |
|
rs121913377
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
On PTC univariate analysis, EGFR-H correlated with increasing stage, extrathyroid extension, tumor capsule invasion, adverse pathologic features (any demonstration of extrathyroid extension, tumor capsule invasion, lymphovascular invasion, lymph node metastasis, and/or distant metastasis), and BRAF(V600E) mutations.
|
23746767 |
2013 |
|
rs121913377
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Patients with BRAF(V600E) wild-type primary tumor do not appear to acquire the mutation in their metastases, and BRAF(V600E) is associated with poorer outcomes in metastatic patients.
|
20635392 |
2011 |
|
rs121913377
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
NRAS mutant/BRAF wild type metastatic deposits were identified in three patients, with one patient having a BRAF V600E mutant metastatic tumour.
|
31023480 |
2019 |
|
rs121913377
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Unexpectedly, V599 and V599E mutations were absent in cutaneous/subcutaneous metastases derived from acrolentiginous melanomas as preceding primary tumours.
|
15935100 |
2005 |
|
rs121913377
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
They include BRAF(V600E) and AKT that affect tumor initiation, progression and metastasis.
|
24362526 |
2014 |
|
rs121913377
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
After controlling for the effect of MS status, there was no correlation of RNF43 frameshift mutation with distant metastasis (OR = 1.57 [0.75, 3.28]) and advanced TNM stages (OR = 0.98 [0.58, 1.67]), but RNF43 frameshift mutations still occur more frequently in right colon (OR = 2.58 [1.49, 4.47]) and with BRAF V600E mutation (OR = 1.94 [1.22, 3.10]).
|
31122752 |
2019 |
|
rs121913377
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
We investigated whether the presence of a BRAF V600E mutation is differentially associated with sites and appearance of metastatic disease in patients matched by primary tumor location.
|
27956538 |
2016 |
|
rs121913377
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
We therefore analyzed the correlation of BRAF V600E and ERK-activation in 20 malignant melanomas and 21 subsequently evolved, paired metastases of the same donor by BRAF exon 15 DNA sequencing and phospho-specific immunohistochemistry for ERK.
|
20605766 |
2010 |
|
rs121913377
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E mutation testing of colorectal tumors demonstrating aberrant MLH1 protein expression by IHC was the most common secondary tumor test, with 53% of laboratories performing the test; 15% of laboratories also applied the BRAF V600E test to endometrial tumors with aberrant MLH1 expression despite no evidence for its utility.
|
30294856 |
2018 |
|
rs121913377
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
All four patients with distant metastasis had BRAF(V600E) mutation.
|
22767446 |
2012 |
|
rs121913377
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
We also studied the role of BRAF V600E mutation in a set of melanoma patients who had been investigated for sentinel node metastasis.
|
25442222 |
2015 |
|
rs121913377
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Interestingly, by droplet digital PCR, the V600E mutation was also detected in the first primary, and the V600K in the second primary and metastases.
|
30222690 |
2019 |
|
rs121913377
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
However, there was no significant association between BRAF(V600E) mutation and factors including age > 45 (OR = 0.98; 95%CI = 0.89-1.07), tumor size (OR = 0.84; 95%CI = 0.64-1.09) and distant metastasis (OR = 1.23; 95%CI = 0.67-2.27).
|
26871894 |
2016 |
|
rs121913377
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
The higher incidence of p.V600E mutations in LNs may prompt further studies to elucidate if the p.V600E mutation in primary tumors is associated with a higher risk of LN metastasis.
|
25456393 |
2015 |
|
rs121913377
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF(V599E) tended to be associated, although not significantly, with a greater volume and extension of the tumour and with lymph-nodal metastases at surgery.
|
15272920 |
2004 |
|
rs121913377
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
In line with the previous reports, NRAS/BRAF mutations were rare; only one metastatic tumor had an NRAS E61R mutation, and one primary tumor and two metastases harbored BRAF V599E mutations.
|
16098043 |
2005 |
|
rs121913377
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Patients with PTC harboring the BRAF(V600E) mutation seem to display a more aggressive clinical behavior, but little is known about the role of this mutation in crucial processes in the tumor microenvironment, such as tumor adhesion, migration, invasion, and metastasis.
|
21447745 |
2011 |
|
rs121913377
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
This study correlates histological features, immunoreactivity for CK19, HBME, and Gal, and BRAF V600E mutation with lymph node (LN) metastasis and follow-up in FVPTC.
|
25702102 |
2015 |
|
rs121913377
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E was associated with advanced TNM (P < 0.001), more distant metastases (P = 0.025), and worse overall survival (OS, P < 0.001; multivariate HR = 4.2, P = 0.004) in colon cancer patients.
|
25367198 |
2014 |
|
rs121913377
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
In patients with conventional papillary thyroid cancer, BRAF V600E mutation was associated with older age (P = 0.0381), lymph node metastasis (P = 0.0323), distant metastasis (P = 0.045), higher TNM stage (I and II vs. III and IV, P = 0.0389), and recurrent and persistent disease (P = 0.009) with a median follow-up time of 6.0 years.
|
17717450 |
2007 |